Okayama University Medical Research Updates （OU-MRU） Vol.42
August 03, 2017
Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 28 July 2017
Okayama University research: Potential drug for treating chronic pain with few side effects
(Okayama, 28 July) Researchers at Okayama University describe in Proceedings of the National Academy of Sciences the effect of clodronate on the regulation of adenosine triphosphate release and its potential as a drug for the treatment of chronic pain. The compound has few side effects and may also be effective for treating other medical conditions including diabetes.
Typical drugs for treating chronic pain — a condition estimated to affect 20 – 25% of the world’s population — often cause serious side effects such as stomach problems, kidney failure or addiction. Now, a team of researchers led by Yuri Kato and Takaaki Miyaji from Okayama University has identified a compound, clodronate, that inhibits the mechanism triggering chronic pain while having few side effects. Clodronate may therefore be used for future chronic pain drug development. Moreover, the researchers reckon it may also be effective for the treatment of other diseases such as diabetes and neurological disorders.
Acute pain is the result of sensory nerves responding to a (potentially) harmful stimulus, a biological process called nociception. However, inflammation or nerve injuries can trigger pathological nociception — a long-lasting sensation of pain due to the stimulated production of adenosine triphosphate (ATP) molecules that bind to so-called purinergic receptors causing pain responses. The ATP molecules participating in the purinergic signalling processes are carried by vesicular nucleotide transporter (VNUT) protein. Since it is known that suppression of VNUT function leads to an improvement of neuropathological conditions in mice, Moriyama and Miyaji and colleagues looked for a VNUT inhibitor with few side effects.
The researchers tested clodronate, a molecule belonging to the class of bisphosphonates, compounds used for treating osteoporosis. Clodronate does not contain nitrogen, a characteristic known to decrease therapeutic effect for osteoporosis and the number of side effects. Experiments on proteoliposomes showed that clodronate is a potent inhibitor of VNUT, whereas injections of clodronate in wild-type mice showed that it attenuated chronic neuropathic and inflammatory pain.
The scientists confirmed that clodronate has few side effects, and noted that its therapeutic effectiveness is stronger than that of other widespread drugs for neuropathic pain. Clodronate’s potent inhibition of VNUT also makes it a highly relevant candidate drug for the treatment of diabetic symptoms. Given that clodronate is currently clinically approved in many countries for the treatment of osteoporosis, the drug has great potential. Accordingly, Kato and Miyaji and colleagues conclude their report by noting that “further studies regarding the wide range of applications of clodronate are currently in progress in our laboratories.”
In medicine, pain lasting a long time — typically, 3 months or more — is called chronic, as opposed to acute pain. Chronic pain can be neuropathic, when the nervous system is damaged, or nociceptive, when inflammation causes nociceptors (pain sensors) to be triggered permanently.
Current drugs for the treatment of chronic pain, notably opioids like morphine, have various side effects, including stomach or kidney dysfunction, drug addiction, drowsiness and vomiting. Yuri Kato and Takaaki Miyaji and colleagues have now identified a potential non-opioid drug, clodronate, that suppresses chronic pain by inhibiting the release of adenosine triphosphate (ATP), a mechanism involved in chronic pain.
In living organisms, purinergic signalling is a way of passing on signals outside cells. It involves purines, particular types of aromatic molecules containing nitrogen, and so-called purinergic receptors in cells. The purinergic signalling mechanism associated with chronic pain involves the purine adenosine triphosphate (ATP), a molecule playing an important role in biological energy transfer processes; ATP is carried by vesicular nucleotide transporter (VNUT) protein. The present study shows that clodronate inhibits VNUT, which in turn attenuates neuropathic and nociceptive pain. Since clodronate has few side effects and since it has already been clinically approved in many countries, it is a promising drug for the treatment of chronic pain.
Yuri Kato, Miki Hiasa, Reiko Ichikawa, Nao Hasuzawa, Atsushi Kadowaki, Ken Iwatsuki, Kazuhiro Shima, Yasuo Endo, Yoshiro Kitahara, Tsuyoshi Inoue, Masatoshi Nomura, Hiroshi Omote, Yoshinori Moriyama & Takaaki Miyaji. Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. Proceedings of the National Academy of Sciences, August 1, vol.114, no.31, 2017.
Associate Professor Takaaki Miyaji, Ph.D.
Advanced Science Research Center, Okayama University,
Tsushima-naka 1-1-1, Okayama city, Okayama 700-8530,
For inquiries, please contact us by replacing (a) with the @ mark.
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYIOkayama University Image Movie (You Tube): https://www.youtube.com/watch?v=KU3hOIXS5kk
Okayama University Medical Research Updates （OU-MRU）Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testingVol.2：Ensuring a cool recovery from cardiac arrestVol.3：Organ regeneration research leaps forwardVol.4：Cardiac mechanosensitive integratorVol.5：Cell injections get to the heart of congenital defectsVol.6：Fourth key molecule identified in bone developmentVol.7：Anticancer virus solution provides an alternative to surgeryVol.8：Light-responsive dye stimulates sight in genetically blind patientsVol.9：Diabetes drug helps towards immunity against cancerVol.10：Enzyme-inhibitors treat drug-resistant epilepsyVol.11：Compound-protein combination shows promise for arthritis treatmentVol.12：Molecular features of the circadian clock system in fruit fliesVol.13：Peptide directs artificial tissue growthVol.14：Simplified boron compound may treat brain tumoursVol.15：Metamaterial absorbers for infrared inspection technologiesVol.16：Epigenetics research traces how crickets restore lost limbsVol.17：Cell research shows pathway for suppressing hepatitis B virusVol.18：Therapeutic protein targets liver diseaseVol.19：Study links signalling protein to osteoarthritisVol.20：Lack of enzyme promotes fatty liver disease in thin patientsVol.21：Combined gene transduction and light therapy targets gastric cancerVol.22：Medical supportive device for hemodialysis catheter punctureVol.23：Development of low cost oral inactivated vaccines for dysenteryVol.24：Sticky molecules to tackle obesity and diabetesVol.25：Self-administered aroma foot massage may reduce symptoms of anxietyVol.26：Protein for preventing heart failureVol.27：Keeping cells in shape to fight sepsisVol.28：Viral-based therapy for bone cancerVol.29：Photoreactive compound allows protein synthesis control with lightVol.30：Cancer stem cells’ role in tumor growth revealedVol.31：Prevention of RNA virus replicationVol.32：Enzyme target for slowing bladder cancer invasionVol.33：Attacking tumors from the insideVol.34：Novel mouse model for studying pancreatic cancerVol.35：Potential cause of Lafora disease revealedVol.36：Overloading of protein localization triggers cellular defectsVol.37：Protein dosage compensation mechanism unravelledVol.38：Bioengineered tooth restoration in a large mammalVol.39：Successful test of retinal prosthesis implanted in ratsVol.40：Antibodies prolong seizure latency in epileptic miceVol.41：Inorganic biomaterials for soft-tissue adhesion